Published in final edited form as:

Biochem Biophys Res Commun. 2012 September 7; 425(4): 931–937. doi:10.1016/j.bbrc.2012.08.013.

Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies

Weizao Chen^{a,*}, Yang Feng^a, Yanping Wang^{a,b}, Zhongyu Zhu^a, and Dimitre S. Dimitrov^a

^aProtein Interactions Group, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, USA

^bThe Basic Research Program, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, USA

Abstract

Development of successful AIDS vaccine immunogens continues to be a major challenge. One of the mechanisms by which HIV-1 evades antibody-mediated neutralizing responses is the remarkable conformational flexibility of its envelope glycoprotein (Env) gp120. Some recombinant gp120s do not preserve their conformations on gp140s and functional viral spikes, and exhibit decreased recognition by CD4 and neutralizing antibodies. CD4 binding induces conformational changes in gp120 leading to exposure of the coreceptor-binding site (CoRbs). In this study, we test our hypothesis that CD4-induced (CD4i) antibodies, which target the CoRbs, could also induce conformational changes in gp120 leading to better exposed conserved neutralizing antibody epitopes including the CD4-binding site (CD4bs). We found that a mixture of CD4i antibodies with gp120 only weakly enhanced CD4 binding. However, such interactions in single-chain fusion proteins resulted in gp120 conformations which bound to CD4 and CD4bs antibodies better than the original or mutagenically stabilized gp120s. Moreover, the two molecules in the fusion proteins synergized with each other in neutralizing HIV-1. Therefore, fusion proteins of gp120 with CD4i antibodies could have potential as components of HIV-1 vaccines and inhibitors of HIV-1 entry, and could be used as reagents to explore the conformational flexibility of gp120 and mechanisms of entry and immune evasion.

Keywords

HIV-1; gp120; stabilization; CD4; CD4i antibody; CD4bs antibody

1. Introduction

HIV-1 entry is initiated by binding of its envelope glycoprotein (Env) gp120 to the primary receptor CD4 on the target cell surface [1]. The binding induces extensive conformational changes in gp120, resulting in formation of the coreceptor-binding site and enabling binding of gp120 to a coreceptor, either CCR5 or CXCR4. Therefore, the CD4-binding site (CD4bs) and coreceptor-binding site (CoRbs) on gp120 are two conserved structures that can be

*Corresponding author. Mailing address: Miller Drive, Building 469, Room 144, Frederick, MD 21702, USA; Phone: (+1) 301-846-1770; Fax: (+1) 301-846-5598; chenw3@mail.nih.gov.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

(sense); TSF, 5'-GTGAGCTCCCAGCTGCTGCTGAAC-3' (sense); TSR, 5'-CTGGGAGCTCACCCTGG-3' (antisense); SWF, 5'-GTGATGCACTGGTTCAACTGCGGC-3' (sense); SWR, 5'-GAACCAGTGCATCACGATCTC-3' (antisense); m36F, 5'-TGGTTTCGCTACCGTGGCCAGCCGGCCAGGTGCAGCTGGTG-3' (sense); m36.4R2, 5'-TGAACCGCCTCCACCGCTCCCTCCACCGCCACTTCCCCGCCACCGCTGCCACCC CC TCCTGAGGAGACGGTGAC-3' (antisense); SCF1, 5'-AGCGGTGGAGGCGGTTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCAGAGGT GGT GCTGGGCAAC-3' (sense); M9F, 5'-TGACGGGCCCAGCCGGCCGTGTTGACACAGTCTCCA-3' (sense); M9R, 5'-TGAACCGCCTCCACCGCTCCCTCCACCGCCACTTCCCCGCCACCGCTGCCACCC CC TCCAGAGGAGACGTTGACCAGGGTTCC-3' (antisense); SCF2, 5'-AGCGGTGGAGGCGGTTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCAGAGAT GGA CCTGGAGAAC-3' (sense); m36.4F1, 5'-ACGAAGCTTCAGGTGCAGCTGGTGAC-3' (sense); 140F, 5'-AGCGGTGGAGGCGGTTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCAAAGCT GTG GGTGACCGTG-3' (sense); and 140R, 5'-CGGGGCCCCGCTGTCCATGTGCTGCCG-3' (antisense).

For cloning of gp120_{MS}, the gene fragment was PCR amplified with primers MSF and SCR1. To generate gp120_{SC}, three gene fragments were amplified with primer pairs SCF/TSR, TSF/SWR, and SWF/SCR1, respectively. Full-length gp120_{SC} gene was assembled by overlapping PCR with the three gene fragments as templates (in the same molarity) and primers SCF and SCR1. To construct m36.4-gp120_{SC}, m36.4 and gp120_{SC} gene fragments were PCR amplified with primer pairs m36F/m36.4R2 and SCF1/SCR1, respectively. Gp120_{SC} was joined to the 3' end of m36.4 by overlapping PCR using primers m36F and SCR1. m9-gp120_{SC} and m36.4-gp120_{MS} were generated in the same way, with the substitution of primer pairs M9F/M9R and SCF2/SCR1 for amplification of scFv m9 and gp120_{MS} gene fragments, respectively, and M9F/SCR1 and m36F/SCR1 for overlapping PCR, respectively. All final PCR products were digested with SfiI and PmeI, and cloned into pSecTagB. To generate m36.4-gp140_{SC}, m36.4 and gp140_{SC} gene fragments were amplified by PCR with primers m36.4F1/m36.4R2 and 140F/140R, respectively. Gp140_{SC} was linked to m36.4 by overlapping PCR using primers m36.4F1 and 140R. The resultant product was digested with HindIII and ApaI, and cloned into pSecTagB.

2.3. Protein expression and purification

Gp120s, gp140s, and their fusion proteins with CD4i antibodies were expressed and purified from 293 free style cell culture supernatants, as described previously [18].

2.4. Size-exclusion chromatography

A Superdex75 10/300 GL column (GE Healthcare, Piscataway, NJ) was calibrated with protein molecular mass standards of 75 kDa Conalbumin, 158 kDa aldolase, 440 kDa ferritin and 669 kDa thyroglobulin. Purified proteins in PBS (pH 7.4) were loaded onto the pre-equilibrated column and eluted with PBS at 0.5 ml/min.

2.5. ELISA

ELISA was performed as described (6). The half-maximal binding (EC₅₀) was calculated by fitting the data to the Langmuir adsorption isotherm.

2.6. Surface plasmon resonance (SPR)

The binding kinetics of sCD4 with HIV-1 Envs and their fusion proteins were assessed by SPR analysis on Biacore X100 (GE Healthcare) using a single-cycle approach as described previously [13].

2.7. Pseudovirus neutralization assay

HIV-1 pseudoviruses were generated and the neutralization assay was performed as described previously (6) except that the target cells HOS-CD4-CCR5 were first incubated with the Envs for 30 min before viruses were added.

3. Results and discussion

3.1. Generation of truncated HIV-1 gp120s and their fusion proteins with CD4i antibodies

Truncated HIV-1 gp120s with an N-terminal deletion up to residue 82, a C-terminal deletion down to residue 493, and variable loop deletions were previously described and widely used for crystallization and other experimental analysis [1,19]. Such gp120 derivatives, also termed gp120 cores, could be further conformationally stabilized by structure-guided mutagenesis and have been evaluated for their ability to elicit broadly neutralizing antibodies *in vivo* [6,9,10,11]. In this study, we generated two truncated gp120s, one (gp120_{SC}) from a clade-B and the other (gp120_{MS}) from a clade-A virus isolated from chronically HIV-1-infected patients. For consistency with previous studies [1,19], both gp120 sequences ranged from amino acid residues 83 to 492 but they contained intact variable loops (Fig. 1A). Their corresponding gp140s, gp140_{SC} and gp140_{MS}, were described previously [13,14]. To generate single-chain fusion proteins, the gp120s and gp140s were fused to the C terminus of CD4i antibodies, m36.4 or m9, via a polypeptide linker composed of six repeats of G₄S motif (Fig. 1A). m36.4 is an affinity-matured version of the first reported engineered human antibody heavy chain variable domain (VH) m36, which targets a CD4i epitope [18]. m9 is an affinity-matured version of the CD4i antibody X5 [15] and is in the format of single-chain variable fragment (scFv). A stabilized gp120_{SC}, designated gp120_{SCm}, was generated by introducing two amino acid mutations (T257S +S375W) including a substitution of the Phe43 cavity in the CD4bs, according to a previously reported approach [11].

All HIV-1 Envs and their fusion proteins were expressed and purified from 293 free style cell culture supernatants with favorable yields (5–10 mg l⁻¹). They ran on reducing SDS-PAGE with apparent molecular weights larger than their calculated molecular weights due to heavy glycosylation (Fig. 1B). On a size-exclusion chromatography, the gp120s eluted as a mixture of monomer and dimer (Fig. 1C), in agreement with a previous study [20]. The m36.4-gp120 fusion proteins eluted similarly although a larger quantity of m36.4-gp120_{SC} was in a dimeric state, and no higher-order oligomers were observed.

3.2. Gp120_{SC} showed largely diminished binding to CD4 and CD4i antibodies weakly enhanced the interaction

It has been previously observed that truncated HIV-1 gp120 lacking hypervariable loops and segments of its N and C termini could have reduced (up to 10 folds) affinity for CD4 compared with full-length gp120 and gp140 [21]. To assess how well the truncated gp120s we generated could bind to CD4, we performed ELISA and SPR analysis. In SPR analysis, we used two-domain human sCD4, which is in a monomeric state according to our previous study [13], while in ELISA assays, an Fc-fusion protein of sCD4 (sCD4Fc) [13] was used for consistency of valency with several mAbs tested (mostly in IgG1 format). In an ELISA assay, gp140_{SC} strongly bound to sCD4Fc with an EC₅₀ of approximately 2 nM (Fig. S1A). However, gp120_{SC} showed a great decrease in binding (EC₅₀, > 100 nM). In a SPR analysis,

gp120_{SC} had an affinity for sCD4 ($K_D = 104$ nM) about 80-fold lower than that ($K_D = 1.3$ nM) of gp140_{SC} (Table 1). These results suggest an alteration of the CD4bs conformation in the context of gp120_{SC}. CD4 induces conformational changes in gp120 leading to the exposure/formation of CD4i epitopes. To find out whether CD4i antibodies could do likewise, we measured the binding of sCD4Fc to gp120_{SC} in the absence or presence of m36.4 or m9. The results showed that m36.4 and m9 at a constant concentration of 3.5 μ M weakly enhanced sCD4Fc binding to gp120_{SC} but not to gp140_{SC} (Fig. S1). The enhancement effects on gp120_{SC} are minor likely due to the relatively low local antibody concentrations and generally very weak binding of CD4i antibodies to independently folded gp120 in the absence of CD4.

3.3. CD4i antibody-gp120_{SC} fusion proteins exhibited much better binding to CD4 and significantly better binding to CD4bs antibodies than gp120_{SC}

To test whether further increasing the local concentration of CD4i antibodies could have more pronounced enhancement effects, we generated fusion proteins of the Envs with CD4i antibodies. In our previous study [14], we found that fusing m36 to the C terminus of a cargo protein via a polypeptide linker resulted in largely decreased binding of m36 to HIV-1 gp120 likely because the linker, which is in close proximity to the antigen-binding site of m36, interrupts the interaction. Therefore, we decided to join m36.4 and m9 to the N terminus of the Envs. In an ELISA assay (Fig. 2), sCD4Fc bound to m36.4-gp120_{SC} coated on 96-well plates with an EC_{50} (2 nM) much lower than that (>100 nM) of gp120_{SC}. Interaction of sCD4Fc with m36.4 was not detected suggesting that the enhanced binding of sCD4Fc to m36.4-gp120_{SC} was gp120-specific. Compared to gp120_{SC}, m36.4-gp120_{SC} also showed a considerable increase in binding to the well-characterized CD4bs mAbs, b12 [22] and m18 [17], while the increase in binding to VRC01 [2] and m14 [16] was less significant. VRC01 was the only antibody that bound to gp120_{SC} better than to gp140_{SC}. When 2G12 [23], a bnmAb targeting a conserved cluster of oligomannose glycans on gp120, was tested, m36.4-gp120_{SC} exhibited a binding strength comparable with that of gp120_{SC}, suggesting that fusion to m36.4 did not alter the glycosylation of gp120 with respect to 2G12 recognition. In all cases, m36.4-gp120_{SC} showed comparable or even better binding activities than gp140_{SC}. Enhanced recognition by sCD4Fc was also observed when gp120_{SC} was fused to m9 (Fig. S2A). In the SPR-based analysis (Table 1), the affinities ($K_D = 0.73$ and 1.8 nM, respectively) of m36.4-gp120_{SC} and m9-gp120_{SC} for sCD4 were comparable with that ($K_D = 1.3$ nM) of gp140_{SC} but much higher than that ($K_D = 104$ nM) of gp120_{SC}, in agreement with the results from ELISA. Notably, the changes in affinity were mostly caused by the altered dissociation constants although the association constants also contributed.

To test whether the enhancement could be achieved with a gp140 or a gp120 that does not show largely decreased binding compared to the corresponding gp140, we fused m36.4 to gp140_{SC} and gp120_{MS} (Fig. 1). In contrast to the effects on gp120_{SC}, m36.4 was ineffective in enhancing sCD4 interaction with gp140_{SC} and gp120_{MS}, which alone had an affinity comparable with that of gp140_{MS} (Table 1). In an ELISA assay, however, m36.4-gp120_{MS} and m36.4-gp140_{SC} bound to sCD4Fc about three-fold better than gp120_{MS} and gp140_{SC}, respectively (Figs. S2B and S2C). These results suggest that although fusion of CD4i antibodies to gp140s or gp120s with well-preserved CD4bs may not increase their affinity for CD4, it could still have an impact on gp120 conformation leading to higher avidity binding to CD4.

3.4. m36.4-gp120_{SC} bound to CD4 and antibodies better than mutagenically stabilized gp120_{SC}

To compare our approach to a previously reported structural and mutagenic strategy for gp120 stabilization, we generated gp120_{SCm}, which carried T257S+S375W double mutations (Fig. 1A). In previous studies [9,11], gp120 derivatives with the same two mutations demonstrated a significant increase in gp120 affinity for sCD4 and CD4i antibodies. Gp120_{SCm} was tested for ELISA binding to sCD4Fc, CD4bs antibodies b12, VRC01 and m14, and CD4i antibody 17b [24]. As shown in Figure 3, gp120_{SCm} bound to sCD4Fc slightly better than gp120_{SC}. However, it showed comparable (b12 and VRC01), decreased (17b) or no binding (m14) to the antibodies tested. In all cases, m36.4-gp120_{SC} exhibited stronger interactions than both gp120_{SC} and gp120_{SCm}. 17b bound to gp140_{SC} about five-fold better than to m36.4-gp120_{SC}. In agreement with the ELISA data, the results from SPR analysis showed that gp120_{SCm} had an affinity for sCD4 of 59 nM, which was about two-fold higher than that (104 nM) of gp120_{SC} but still much lower than those (0.73 and 1.8 nM, respectively) of m36.4-gp120_{SC} and m9-gp120_{SC} (Table 1).

The T257S+S375W double-mutation strategy was developed and evaluated mainly using conserved gp120 cores with shortened or deleted variable loops [9,11]. It is therefore likely that the gp120 variable loops, which remained intact in the gp120s we generated, may impair the stabilization effects of the T257S+S375W mutations. Surprisingly, the mutagenic strategy appeared to disrupt the gp120 conformations required for interaction with some CD4bs antibodies [9], which was confirmed in our study by using m14 (Fig. 3). In contrast, our approach led to an increase in binding to all CD4bs antibodies tested (Figs. 2 and 3). This can be particularly important for the use of gp120 as vaccine immunogens because extensive exposure of the conserved epitopes for neutralizing antibodies could be critical for elicitation of broadly neutralizing responses. The breadth of serum neutralization has been mapped to multiple epitope specificities [25]. Moreover, fusion to a CD4i antibody could partially shield the CoRbs from the immune system. CD4i antibodies are abundant in patients with HIV-1 infection [26] but generally do not or only weakly neutralize the virus as full-size antibody molecules due to steric occlusion of their epitopes [18,24]. Therefore, sequential immunization with gp120 fused to different CD4i antibodies might partially avoid or minimize elicitation of such antibodies while diverting the immune responses to other conserved structures on gp120 such as the CD4bs.

3.5. Potent neutralizing activity of m36.4-gp120_{SC}

Recombinant Envs are potent HIV-1 entry inhibitors because they block the attachment of the virus to the cell membrane-associated CD4. To assess how well m36.4-gp120_{SC} could prevent HIV-1 infection, we conducted a pseudovirus neutralization assay. The results showed that gp120_{SC} and gp120_{SCm} neutralized two primary isolates from clade B, Bal and JRFL, much less potently than gp140_{SC} (Fig. 4), in correlation with their relative binding strengths in ELISA and SPR. m36.4 as an Fc-fusion protein, m36.4h1Fc, did not or only very weakly neutralized the viruses due to an increase in molecular size, in agreement with our previous study [14]. Surprisingly, m36.4-gp120_{SC} displayed neutralizing activities (IC₅₀s, 5 nM) against both isolates four-fold higher than those (IC₅₀s, 20 nM) of gp140_{SC} despite their comparable binding to sCD4, suggesting synergistic effects of the antibody-gp120 fusion on neutralizing the viruses.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This project was supported by the Intramural Research Program of the NIH, National Cancer Institute, Frederick National Laboratory for Cancer Research.

References

1. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. *Nature*. 1998; 393:648–659. [PubMed: 9641677]
2. Wu X, Yang ZY, Li Y, Hogenkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. *Science*. 2010; 329:856–861. [PubMed: 20616233]
3. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhaghoorsingh S, Willems B, Zekveld MJ, Dreja H, O'Sullivan E, Pade C, Orkin C, Jeffs SA, Montefiori DC, Davis D, Weissenhorn W, McKnight A, Heeney JL, Sallusto F, Sattentau QJ, Weiss RA, Lanzavecchia A. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. *PLoS ONE*. 2010; 5:e8805. [PubMed: 20098712]
4. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. *Science*. 2009; 326:285–289. [PubMed: 19729618]
5. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Wilson IA, Burton DR, Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. *Nature*. 2011; 477:466–470. [PubMed: 21849977]
6. Xiang SH, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, Wyatt R, Wang L, Hendrickson WA, Doyle ML, Sodroski J. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. *J Virol*. 2002; 76:9888–9899. [PubMed: 12208966]
7. Martin G, Burke B, Thai R, Dey AK, Combes O, Ramos OH, Heyd B, Geonnotti AR, Montefiori DC, Kan E, Lian Y, Sun Y, Abache T, Ulmer JB, Madaoui H, Guerois R, Barnett SW, Srivastava IK, Kessler P, Martin L. Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic. *J Biol Chem*. 2011; 286:21706–21716. [PubMed: 21487012]
8. Fouts TR, Tuskan R, Godfrey K, Reitz M, Hone D, Lewis GK, DeVico AL. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. *J Virol*. 2000; 74:11427–11436. [PubMed: 11090138]
9. Zhou T, Xu L, Dey B, Hessel AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD. Structural definition of a conserved neutralization epitope on HIV-1 gp120. *Nature*. 2007; 445:732–737. [PubMed: 17301785]
10. Dey B, Svehla K, Xu L, Wycuff D, Zhou T, Voss G, Phogat A, Chakrabarti BK, Li Y, Shaw G, Kwong PD, Nabel GJ, Mascola JR, Wyatt RT. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. *PLoS Pathog*. 2009; 5:e1000445. [PubMed: 19478876]
11. Dey B, Pancera M, Svehla K, Shu Y, Xiang SH, Vainshtein J, Li Y, Sodroski J, Kwong PD, Mascola JR, Wyatt R. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. *J Virol*. 2007; 81:5579–5593. [PubMed: 17360741]

12. Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD, Phogat A, Forsell MN, Karlsson Hedestam GB, Mascola JR, Wyatt RT. Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site. *J Biol Chem.* 2012; 287:5673–5686. [PubMed: 22167180]
13. Chen W, Feng Y, Gong R, Zhu Z, Wang Y, Zhao Q, Dimitrov DS. Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. *J Virol.* 2011; 85:9395–9405. [PubMed: 21715496]
14. Chen W, Xiao X, Wang Y, Zhu Z, Dimitrov DS. Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. *Antiviral Res.* 2010; 88:107–115. [PubMed: 20709110]
15. Zhang MY, Shu Y, Rudolph D, Prabakaran P, Labrijn AF, Zwick MB, Lal RB, Dimitrov DS. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. *J Mol Biol.* 2004; 335:209–219. [PubMed: 14659751]
16. Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, Zhang PF, Bouma P, Zwick M, Choudhary A, Montefiori DC, Broder CC, Burton DR, Quinnan GV Jr, Dimitrov DS. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. *J Virol.* 2004; 78:9233–9242. [PubMed: 15308718]
17. Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, Bouma P, Choudhary A, Feng YR, Sanz I, Rybak S, Broder CC, Quinnan GV, Evans T, Dimitrov DS. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. *J Immunol Methods.* 2003; 283:17–25. [PubMed: 14659896]
18. Chen W, Zhu Z, Feng Y, Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. *Proc Natl Acad Sci U S A.* 2008; 105:17121–17126. [PubMed: 18957538]
19. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. *Nature.* 1996; 384:179–183. [PubMed: 8906795]
20. Center RJ, Earl PL, Lebowitz J, Schuck P, Moss B. The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts. *J Virol.* 2000; 74:4448–4455. [PubMed: 10775580]
21. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, Wyatt R, Sodroski J, Doyle ML. Energetics of the HIV gp120-CD4 binding reaction. *Proc Natl Acad Sci U S A.* 2000; 97:9026–9031. [PubMed: 10922058]
22. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. *J Virol.* 1994; 68:4821–4828. [PubMed: 7518527]
23. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steindl F, Jungbauer A, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. *AIDS Res Hum Retroviruses.* 1994; 10:359–369. [PubMed: 7520721]
24. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, Burton DR. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. *J Virol.* 2003; 77:10557–10565. [PubMed: 12970440]
25. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. *Nature.* 2009; 458:636–640. [PubMed: 19287373]
26. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE, Shaw

GM. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. *J Exp Med*. 2005; 201:1407–1419. [PubMed: 15867093]

Highlights

1. Some recombinant HIV-1 gp120s do not preserve their conformations on gp140s;
2. We hypothesize that CD4i antibodies could induce conformational changes in gp120;
3. CD4i antibodies enhance binding of CD4 and CD4bs antibodies to gp120;
4. CD4i antibody-gp120 fusion proteins could have potential as vaccine immunogens.

Fig. 1. Schematic representation of HIV-1 Envs and biophysical characterization of the purified proteins. (A) Design of truncated gp120s and CD4i antibody-Env fusion proteins. The gp120 sequences range from amino acid residues 83 to 492. The 6 × His denotes a hexahistidine tag and (G₄S)₆ represents a polypeptide linker composed of six repeats of the G₄S motif. The stars indicate the T257S+S375W mutations in gp120. (B) Reducing SDS-PAGE of the purified proteins. (C) Size-exclusion chromatography. The bold arrows shown at the top indicate the elution volumes of the molecular mass standards in PBS: Conalbumin (75 kDa), Aldolase (158 kDa), Ferritin (440 kDa), and Thyroglobulin (669 kDa).

Fig. 2.

ELISA binding of sCD4Fc and mAbs to m36.4-gp120_{SC}. m36.4-gp120_{SC} and the control antigens were coated on 96-well plates. All mAbs except b12, which is an Fc-fusion protein of scFv, are in IgG1 format. Bound sCD4Fc and mAbs were detected by HRP-conjugated goat anti-human IgG (Fc-specific) antibody.

Fig. 3. ELISA binding of sCD4Fc and mAbs to gp120_{SCM}. The gp120 proteins and control antigens were coated on 96-well plates. Bound sCD4Fc and mAbs were detected by HRP-conjugated goat anti-human IgG (Fc-specific) antibody.

Fig. 4. Neutralization of HIV-1 by the Envs and fusion proteins. The pseudotyped viruses were generated from 293T cells and the assays were performed on HOS-CD4-CCR5 cells, as described in Materials and Methods.

Table 1

Binding kinetics of sCD4 with HIV-1 Envs measured by SPR.

HIV-1 Envs	K_a ($M^{-1} s^{-1}$)	K_d (s^{-1})	K_D (nM)
gp140 _{SC}	2.4×10^5	3.0×10^{-4}	1.3
gp120 _{SC}	8.1×10^4	8.4×10^{-3}	104
gp120 _{SCM}	1.0×10^5	6.1×10^{-3}	59
m36.4-gp120 _{SC}	7.7×10^4	5.6×10^{-5}	0.73
m9-gp120 _{SC}	1.6×10^5	2.9×10^{-4}	1.8
m36.4-gp140 _{SC}	2.2×10^6	4.2×10^{-3}	1.9
gp140 _{MS}	3.9×10^5	1.4×10^{-4}	0.36
gp120 _{MS}	2.3×10^6	4.8×10^{-4}	0.21
m36.4-gp120 _{MS}	2.5×10^6	3.9×10^{-4}	0.15

 K_a , association constant. K_d , dissociation constant. K_D , equilibrium dissociation constant.